항-VEGF 치료제 시장 : 시장 기회, 성장 촉진요인, 산업 동향 분석(2025-2034년)

The Global Anti-VEGF Therapeutics Market, valued at USD 13.8 billion in 2024, is poised to expand steadily with a projected CAGR of 1.9% from 2025 to 2034. This growth is primarily driven by a combination of factors such as the increasing prevalence of eye diseases, the aging global population, and heightened awareness surrounding available treatment options. Age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion are among the leading conditions fueling the demand for anti-VEGF therapies. These diseases are typically associated with abnormal blood vessel growth, which can be effectively treated using VEGF inhibitors. As these therapies offer significant improvements in vision and overall disease management, they have become an essential part of ophthalmology.

The market is being shaped by key segments, including prominent anti-VEGF therapies that offer impressive clinical outcomes and longer dosing intervals. In 2024, one such therapy captured a substantial 46.6% market share due to its reduced injection frequency, enhancing patient convenience and adherence to treatment regimens. The ability to receive fewer injections has made this therapy the preferred choice among healthcare providers, contributing to its growing adoption.

In terms of application, macular edema, diabetic retinopathy, retinal vein occlusion, AMD, and myopic choroidal neovascularization represent the main categories within the market. Macular edema, which often results from diabetes and vascular complications, led the market with a 47.5% share in 2024. The rising global prevalence of diabetes has exacerbated the occurrence of macular edema, driving an increased demand for targeted treatments. This shift in prevalence is a significant driver of growth, as more patients are diagnosed and treated for the condition, resulting in a notable uptick in therapeutic needs.

In the U.S., the anti-VEGF therapeutics market reached USD 5.1 billion in 2024, driven by the country's aging population and the high incidence of retinal disorders. AMD remains one of the leading causes of vision impairment, playing a crucial role in market expansion. The advanced healthcare system in the U.S. ensures that patients have broad access to cutting-edge treatments, bolstered by a comprehensive reimbursement framework. This accessibility has allowed more patients to benefit from anti-VEGF therapies, solidifying the U.S. as a dominant force within the global market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of eye diseases
    • 3.2.1.2 Rise in aging population
    • 3.2.1.3 Technological advancements in drug development
    • 3.2.1.4 Growing awareness towards timely treatment of ophthalmic disorders
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Side effects and safety concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Future market trends
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Eylea
• 5.3 Lucentis
• 5.4 Beovu
• 5.5 Vabysmo
• 5.6 Other products

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Macular edema
• 6.3 Diabetic retinopathy
• 6.4 Retinal vein occlusion
• 6.5 Age-related macular degeneration
• 6.6 Myopic choroidal neovascularization

Chapter 7 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 South Korea
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
• 7.6 Middle East and Africa
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 UAE

Chapter 8 Company Profiles

• 8.1 Alcon
• 8.2 Amgen
• 8.3 Bausch Health Companies
• 8.4 Bayer
• 8.5 Biogen
• 8.6 Bristol-Myers Squibb
• 8.7 Coherus BioSciences
• 8.8 Eli Lilly and Company
• 8.9 F. Hoffmann-La Roche
• 8.10 Hoya Corporation
• 8.11 Novartis
• 8.12 Pfizer
• 8.13 Regeneron Pharmaceuticals
• 8.14 Sanofi
• 8.15 Viatris